FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128457788> ?p ?o ?g. }

• W2128457788 endingPage "168" @default.
• W2128457788 startingPage "163" @default.
• W2128457788 abstract "Objective: To evaluate the effects of adalimumab on patient-reported outcomes of joint-related and skin-related functional impairment, health-related quality of life, fatigue and pain in patients with psoriatic arthritis (PsA). Methods: Patients with moderately- to severely- active PsA were treated with adalimumab, 40 mg, every other week, or placebo, in this 24-week, randomised, controlled trial. Patient-reported outcomes included the Health Assessment Questionnaire Disability Index (HAQ DI), Short-Form 36 Health Survey (SF-36), the Functional Assessment of Chronic Illness Therapy—Fatigue (FACIT-Fatigue) Scale and the Dermatology Life Quality Index (DLQI). Results: Adalimumab (n = 151) and placebo (n = 162) groups were comparable with respect to baseline demographics and disease severity. Significant changes from baseline in HAQ DI were reported for adalimumab v placebo (−0.4 v −0.1, p<0.001) at both 12 and 24 weeks. At week 24, significant improvements in the SF-36 domains of physical functioning, role-physical, bodily pain, general health, vitality and social functioning, as well as the physical component summary score, were observed for adalimumab versus placebo (p<0.01). These reported changes in HAQ DI and SF-36 were also clinically important. Significantly more patients treated with adalimumab had complete resolution of functional loss (HAQ DI = 0) and dermatological-related functional limitations (DLQI = 0) compared with placebo at weeks 12 and 24 (p⩽0.001). Adalimumab led to significantly greater improvements in FACIT-Fatigue scores, pain scores, and disease activity measures versus placebo at 12 and 24 weeks (p<0.001 for all). Conclusions: Adalimumab improved physical-related and dermatological-related functional limitations, HRQOL, fatigue and pain in patients with PsA treated for 24 weeks." @default.
• W2128457788 created "2016-06-24" @default.
• W2128457788 creator A5040915422 @default.
• W2128457788 creator A5047314880 @default.
• W2128457788 creator A5049489990 @default.
• W2128457788 creator A5052241055 @default.
• W2128457788 creator A5081778211 @default.
• W2128457788 creator A5083588439 @default.
• W2128457788 date "2006-08-11" @default.
• W2128457788 modified "2023-10-14" @default.
• W2128457788 title "Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial" @default.
• W2128457788 cites W117628105 @default.
• W2128457788 cites W165899179 @default.
• W2128457788 cites W1777824885 @default.
• W2128457788 cites W1975900036 @default.
• W2128457788 cites W1981498496 @default.
• W2128457788 cites W2007517418 @default.
• W2128457788 cites W2031937485 @default.
• W2128457788 cites W2037377025 @default.
• W2128457788 cites W2038962823 @default.
• W2128457788 cites W2041499523 @default.
• W2128457788 cites W2043469120 @default.
• W2128457788 cites W2063931484 @default.
• W2128457788 cites W2078157933 @default.
• W2128457788 cites W2096991001 @default.
• W2128457788 cites W2101572423 @default.
• W2128457788 cites W2102632616 @default.
• W2128457788 cites W2112630141 @default.
• W2128457788 cites W2119275077 @default.
• W2128457788 cites W2128840310 @default.
• W2128457788 cites W2133696182 @default.
• W2128457788 cites W2133991692 @default.
• W2128457788 cites W2137884440 @default.
• W2128457788 cites W2138763209 @default.
• W2128457788 cites W2139788459 @default.
• W2128457788 cites W2150206066 @default.
• W2128457788 cites W2156796142 @default.
• W2128457788 cites W2158620918 @default.
• W2128457788 cites W2284641729 @default.
• W2128457788 cites W2417907140 @default.
• W2128457788 cites W2433941725 @default.
• W2128457788 cites W28846052 @default.
• W2128457788 cites W4232214719 @default.
• W2128457788 cites W45832520 @default.
• W2128457788 doi "https://doi.org/10.1136/ard.2006.057901" @default.
• W2128457788 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1798491" @default.
• W2128457788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17046964" @default.
• W2128457788 hasPublicationYear "2006" @default.
• W2128457788 type Work @default.
• W2128457788 sameAs 2128457788 @default.
• W2128457788 citedByCount "102" @default.
• W2128457788 countsByYear W21284577882012 @default.
• W2128457788 countsByYear W21284577882013 @default.
• W2128457788 countsByYear W21284577882014 @default.
• W2128457788 countsByYear W21284577882015 @default.
• W2128457788 countsByYear W21284577882016 @default.
• W2128457788 countsByYear W21284577882017 @default.
• W2128457788 countsByYear W21284577882018 @default.
• W2128457788 countsByYear W21284577882019 @default.
• W2128457788 countsByYear W21284577882020 @default.
• W2128457788 countsByYear W21284577882021 @default.
• W2128457788 countsByYear W21284577882022 @default.
• W2128457788 countsByYear W21284577882023 @default.
• W2128457788 crossrefType "journal-article" @default.
• W2128457788 hasAuthorship W2128457788A5040915422 @default.
• W2128457788 hasAuthorship W2128457788A5047314880 @default.
• W2128457788 hasAuthorship W2128457788A5049489990 @default.
• W2128457788 hasAuthorship W2128457788A5052241055 @default.
• W2128457788 hasAuthorship W2128457788A5081778211 @default.
• W2128457788 hasAuthorship W2128457788A5083588439 @default.
• W2128457788 hasBestOaLocation W21284577882 @default.
• W2128457788 hasConcept C126322002 @default.
• W2128457788 hasConcept C142724271 @default.
• W2128457788 hasConcept C159110408 @default.
• W2128457788 hasConcept C16005928 @default.
• W2128457788 hasConcept C1862650 @default.
• W2128457788 hasConcept C204787440 @default.
• W2128457788 hasConcept C27081682 @default.
• W2128457788 hasConcept C2776173921 @default.
• W2128457788 hasConcept C2776260265 @default.
• W2128457788 hasConcept C2777011040 @default.
• W2128457788 hasConcept C2777077863 @default.
• W2128457788 hasConcept C2779134260 @default.
• W2128457788 hasConcept C2779951463 @default.
• W2128457788 hasConcept C2780132546 @default.
• W2128457788 hasConcept C2780564577 @default.
• W2128457788 hasConcept C71924100 @default.
• W2128457788 hasConceptScore W2128457788C126322002 @default.
• W2128457788 hasConceptScore W2128457788C142724271 @default.
• W2128457788 hasConceptScore W2128457788C159110408 @default.
• W2128457788 hasConceptScore W2128457788C16005928 @default.
• W2128457788 hasConceptScore W2128457788C1862650 @default.
• W2128457788 hasConceptScore W2128457788C204787440 @default.
• W2128457788 hasConceptScore W2128457788C27081682 @default.
• W2128457788 hasConceptScore W2128457788C2776173921 @default.
• W2128457788 hasConceptScore W2128457788C2776260265 @default.
• W2128457788 hasConceptScore W2128457788C2777011040 @default.
• W2128457788 hasConceptScore W2128457788C2777077863 @default.

• next